贝达喹啉在结核空洞内扩散动力学为耐药出现提供窗口
研究在结核空洞兔模型中用激光捕获显微切割测量贝达喹啉及TBAJ876、TBAJ587在干酪样物中的空间分布,并结合临床血浆药代动力学建模。模拟显示贝达喹啉需数周至数月才在深部干酪样物达稳态有效浓度,治疗结束后亚治疗浓度可持续长达3年;TBAJ876与TBAJ587更快达到杀菌浓度并缩短亚治疗浓度窗口。
要点
- 贝达喹啉在深部干酪样物需数周至数月达稳态有效浓度。
- 治疗结束后贝达喹啉亚治疗浓度可残留长达3年。
- TBAJ876与TBAJ587较贝达喹啉更快达杀菌浓度并缩短亚治疗窗口。
核心结论
- 贝达喹啉进入和离开干酪样物的缓慢动力学形成亚治疗浓度的时空窗口。
- TBAJ587与TBAJ876的病灶部位模拟预测其耐药出现机会减少。
研究设计与样本
- 研究在已建立结核空洞的兔中给予研究药物。
- 采用激光捕获显微切割方案测量干酪样物中药物浓度随距血供距离的变化。
- 将数据建模并与临床血浆药代动力学模型连接以模拟患者空洞内药物覆盖。
主要发现
- 药代动力学-药效学模拟显示贝达喹啉在深部干酪样物需数周至数月达稳态和有效浓度。
- 贝达喹啉在治疗结束后以亚治疗浓度残留长达3年。
- TBAJ876与TBAJ587较贝达喹啉更快在干酪样物层达到杀菌浓度并缩短治疗后亚治疗浓度窗口。
临床怎么用
- 空洞性结核患者中贝达喹啉的病灶内暴露与血药浓度存在时空差异。
- TBAJ876与TBAJ587的病灶内杀菌浓度达峰更快且亚治疗窗口更短。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cavitary tuberculosis is difficult to cure and constitutes a site of relapse. Bedaquiline has been a wonder drug in the treatment of multidrug-resistant tuberculosis, but emergence of resistance threatens the sustainability of its success. We designed site-of-disease pharmacokinetic studies to spatially resolve the penetration of bedaquiline, and 2 next-generation diarylquinolines, TBAJ876 and TBAJ587, in cavities. METHODS: Rabbits with established cavitary tuberculosis received the study drugs. A laser-capture microdissections scheme was developed to measure drug concentrations as a function of distance from blood supply in caseum. To simulate drug coverage in patient cavities, the data were modeled, and parameter estimates were linked to clinical plasma pharmacokinetic models. RESULTS: Pharmacokinetic-pharmacodynamic simulations in caseum revealed that bedaquiline reaches steady state and efficacious concentrations in deep caseum after several weeks to months and lingers at subtherapeutic concentrations up to 3 years after therapy ends. TBAJ876 and TBAJ587, achieve bactericidal concentrations in caseum layers more rapidly and shorten the window of suboptimal concentrations post treatment compared to bedaquiline. CONCLUSIONS: The slow kinetics of diffusion of bedaquiline into and out of caseum creates spatiotemporal windows of subtherapeutic concentrations. Site-of-disease simulations of TBAJ587 and TBAJ876 predict reduced opportunities for resistance development.
引用
- Bustion AE, Ernest JP, Kaya F, et al. The Kinetics of Bedaquiline Diffusion in Tuberculous Cavities Open a Window for the Emergence of Resistance. J Infect Dis. 2025. PMID: 40464735. doi:10.1093/infdis/jiaf303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。